Your One-Stop Solution for Drug Patent Monitoring
Get time sensitive email alerts like Notice of allowance, Abandoned, Oppositions, NCE1 from different regulatory like USPTO, EPO and Orange Book, etc. to make decisions on generic drug launches.
You need Elixir if you
What does Elixir track?
How Elixir solves the existing problems with
a centralized system and an email
Spreadsheets have become the backbone for patent landscape and clearance search outputs. As your portfolio and assets grow, managing these spreadsheets becomes taxing and tiring. Unlike excel, activities on drug patents Elixir makes performing in-house analysis.
Elixir vs other drug monitoring
How Elixir helped companies like yours?
How many countries does Elixir covers
How Elixir can help you in the process
Most asked questions:
Elixir is a centralized platform aggregating data from various sources, such as USPTO, EPO, and the Orange Book. It uses advanced monitoring tools and algorithms to track drug patents, regulatory updates, and market activities. Users can customize their preferences and receive regular email summaries of their desired information.
Elixir tracks a wide range of information, including patent file histories, PTAB trials, updates from the Orange Book and SPC (Supplementary Protection Certificate), third-party opposition filings, paragraph IV litigation, and identification of first generic entrants. It provides comprehensive coverage of data related to drug patents and regulatory activities.
Various professionals and organizations can benefit from using a drug monitoring tool. This includes those involved in drug research and development, intellectual property management, regulatory affairs, market analysis, and business development within the pharmaceutical industry.
Using spreadsheets for managing patent data can become overwhelming and time-consuming, especially as portfolios and assets grow. Elixir offers a centralized system where users can access and analyze drug patent data in a more efficient and organized manner. It eliminates the need for manually updating spreadsheets and provides a comprehensive overview through a single email summary.
Yes, Elixir is a customizable platform that allows users to tailor their drug monitoring preferences and receive updates specific to their interests. It provides flexibility in tracking the information that is most relevant to their business or research activities.
Elixir provides valuable insights into patent landscapes, competitor activities, and market trends. By staying updated on the latest developments, users can make informed decisions regarding market entry strategies, intellectual property protection, collaborations, and overall business strategies.
Yes, Elixir is designed to provide business intelligence and monitoring capabilities for both bio-pharmaceutical and small-molecule drugs. It covers a wide range of drug types and can accommodate the needs of various organizations operating in the pharmaceutical industry.
By providing real-time updates and comprehensive monitoring of drug patents and market activities, Elixir helps users stay informed about their competitors’ strategies and potential opportunities for market entry. This allows businesses to proactively plan and stay ahead of the competition in a rapidly evolving pharmaceutical landscape.
Usually 20 years.
A drug patent expires 20 years from the date on which the patent application was filed in the United States. Sometimes, a term extension is provided if the original patent was delayed due to secrecy orders, interferences, or appellate review periods.
Generics can be launched once the patent-protected drug surpasses the patent expiry and exclusivity date.
Elixir provides the drug patents list expiring in a particular year, like 2023, 2024, and more.
Drug monitoring is crucial for businesses involved in the pharmaceutical industry as it provides valuable insights into patent expiration dates, competitor activities, market entry opportunities, and regulatory changes. It helps businesses make informed decisions and stay competitive in the market.